Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.

Authors

Christian Schoergenhofer¹, Bernd Jilma¹, Thomas Stimpfl¹, Mario Karolyi², Alexander Zoufaly²

Affiliations

¹ Medical University of Vienna, Vienna, Austria (C.S., B.J., T.S.).
² Kaiser-Franz-Josef-Hospital, Vienna, Austria (M.K., A.Z.).

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / metabolism
Cytochrome P-450 CYP3A Inhibitors / pharmacokinetics
Female
Humans
Inpatients*
Lopinavir / pharmacokinetics*
Male
Middle Aged
Pandemics*
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / metabolism
Ritonavir / pharmacokinetics*
SARS-CoV-2
Young Adult

Substances

Cytochrome P-450 CYP3A Inhibitors
Lopinavir
Ritonavir